Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in previously treated CML-CP with and without T315I mutation
NCT04666259Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Started May 2021; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04666259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666259.